Use of adjuvant systemic therapy increasing for gastrointestinal stromal tumors (GIST)
the ONA take:
Localized gastrointestinal stromal tumors (GISTs) are rarely seen, but are the most common sarcomas in the gastrointestinal tract.
The approval of the drug imatinib and its use in adjuvant systemic treatment post-surgery for adult patients has changed GIST treatment in the last decade.
Researchers from the American Cancer Society wished to evaluate the evolving use of adjuvant therapy in GIST cases. They examined data from the National Cancer Data Base, reviewing the records of 4,694 patients diagnosed with GIST cases after 2004 to establish patterns of adjuvant therapy use.
The investigators discovered that between 2006 and 2007, the use of adjuvant systemic therapy in GIST cases more than doubled, only to drop in 2011. The peak point was in 2009, with nearly 38% of patients reviewed using adjuvant therapy.
Larger tumor size, an older patient age, or a non-minority white patient were all indicators of greater adjuvant systemic therapy use. The authors concluded that adjuvant systemic therapy use has increased by a significant margin in the last decade, acknowledging the modifying factors mentioned.
Results of this study were published online in the American Journal of Clinical Oncology.
Localized GISTs are rarely seen, but are the most common sarcomas in the gastrointestinal tract.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|